vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 8.6%). Over the past eight quarters, LiveRamp Holdings, Inc.'s revenue compounded faster (11.1% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
ESPR vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $212.2M |
| Net Profit | — | $39.9M |
| Gross Margin | — | 71.9% |
| Operating Margin | 50.6% | 18.6% |
| Net Margin | — | 18.8% |
| Revenue YoY | 143.7% | 8.6% |
| Net Profit YoY | — | 255.7% |
| EPS (diluted) | $0.32 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $212.2M | ||
| Q3 25 | $87.3M | $199.8M | ||
| Q2 25 | $82.4M | $194.8M | ||
| Q1 25 | $65.0M | $188.7M | ||
| Q4 24 | $69.1M | $195.4M | ||
| Q3 24 | $51.6M | $185.5M | ||
| Q2 24 | $73.8M | $176.0M | ||
| Q1 24 | $137.7M | $171.9M |
| Q4 25 | — | $39.9M | ||
| Q3 25 | $-31.3M | $27.4M | ||
| Q2 25 | $-12.7M | $7.7M | ||
| Q1 25 | $-40.5M | $-6.3M | ||
| Q4 24 | — | $11.2M | ||
| Q3 24 | $-29.5M | $1.7M | ||
| Q2 24 | $-61.9M | $-7.5M | ||
| Q1 24 | $61.0M | $-5.4M |
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.1% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 72.2% |
| Q4 25 | 50.6% | 18.6% | ||
| Q3 25 | -11.4% | 10.7% | ||
| Q2 25 | 8.6% | 3.7% | ||
| Q1 25 | -34.0% | -6.1% | ||
| Q4 24 | -6.4% | 7.5% | ||
| Q3 24 | -31.0% | 4.0% | ||
| Q2 24 | 3.5% | -3.0% | ||
| Q1 24 | 52.5% | -8.3% |
| Q4 25 | — | 18.8% | ||
| Q3 25 | -35.9% | 13.7% | ||
| Q2 25 | -15.4% | 4.0% | ||
| Q1 25 | -62.2% | -3.3% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -57.2% | 0.9% | ||
| Q2 24 | -83.9% | -4.3% | ||
| Q1 24 | 44.3% | -3.1% |
| Q4 25 | $0.32 | $0.62 | ||
| Q3 25 | $-0.16 | $0.42 | ||
| Q2 25 | $-0.06 | $0.12 | ||
| Q1 25 | $-0.21 | $-0.10 | ||
| Q4 24 | $-0.14 | $0.17 | ||
| Q3 24 | $-0.15 | $0.03 | ||
| Q2 24 | $-0.33 | $-0.11 | ||
| Q1 24 | $0.34 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $403.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $962.3M |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $403.4M | ||
| Q3 25 | $92.4M | $376.9M | ||
| Q2 25 | $86.1M | $371.1M | ||
| Q1 25 | $114.6M | $420.8M | ||
| Q4 24 | $144.8M | $384.3M | ||
| Q3 24 | $144.7M | $348.4M | ||
| Q2 24 | $189.3M | $342.7M | ||
| Q1 24 | $226.6M | $368.9M |
| Q4 25 | $-302.0M | $962.3M | ||
| Q3 25 | $-451.4M | $943.8M | ||
| Q2 25 | $-433.5M | $947.8M | ||
| Q1 25 | $-426.2M | $948.9M | ||
| Q4 24 | $-388.7M | $957.7M | ||
| Q3 24 | $-370.2M | $932.1M | ||
| Q2 24 | $-344.2M | $951.9M | ||
| Q1 24 | $-294.3M | $949.1M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | $1.3B | ||
| Q3 24 | $314.1M | $1.2B | ||
| Q2 24 | $352.3M | $1.2B | ||
| Q1 24 | $373.1M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $57.4M | ||
| Q2 25 | $-31.4M | $-15.8M | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $-35.0M | $45.1M | ||
| Q3 24 | $-35.3M | $55.6M | ||
| Q2 24 | $-7.2M | $-9.3M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $56.8M | ||
| Q2 25 | — | $-16.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | $-35.5M | $55.4M | ||
| Q2 24 | $-7.3M | $-9.6M | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | -68.7% | 29.8% | ||
| Q2 24 | -9.9% | -5.4% | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RAMP
Segment breakdown not available.
